Is there a role for eltrombopag drug levels in paediatric immune thrombocytopenia management?

Br J Haematol

Department of Paediatrics, Stanford University, Stanford, California, USA.

Published: November 2024

AI Article Synopsis

  • The introduction of thrombopoietin mimetics, like romiplostim and eltrombopag, has significantly changed how pediatric immune thrombocytopenia is treated.
  • Dosing for eltrombopag varies based on patient age, liver function, and ethnicity, but similar doses can lead to different side effects and platelet counts among children.
  • There is a hypothesis that the varying levels of eltrombopag in the bloodstream may be influencing these different responses to the medication.

Article Abstract

Paediatric immune thrombocytopenia treatment was revolutionized with the advent of the thrombopoietin mimetics romiplostim and eltrombopag. For eltrombopag, dosing recommendations have been based on patients' ages (with dose reductions for those with hepatic impairment and for some of East Asian ethnicity) and titrated based on platelet counts and adverse drug reactions. However, it is clear that identical eltrombopag dosing for paediatric patients can result in variable side effects and platelet counts, raising the question as to whether variable eltrombopag plasma concentrations are responsible for these differing drug responses. Commentary on: Dong et al. Exploratory study on the individualized application of eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring. Br J Haematol 2024; 205:1930-1937.

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.19757DOI Listing

Publication Analysis

Top Keywords

paediatric immune
12
immune thrombocytopenia
12
eltrombopag dosing
8
platelet counts
8
eltrombopag
5
role eltrombopag
4
drug
4
eltrombopag drug
4
drug levels
4
paediatric
4

Similar Publications

Internationally, vaccination rates among adolescents with intellectual and developmental disability (IDD) are lower than those of the general population. Little research has addressed this issue. This study investigates the experiences of vaccinating adolescents with IDD in special education settings in Australia, with a focus on student engagement.

View Article and Find Full Text PDF

Phytic acid-based nanomedicine against mTOR represses lipogenesis and immune response for metabolic dysfunction-associated steatohepatitis therapy.

Life Metab

December 2024

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi'an, Shaanxi 710032, China.

Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common chronic liver diseases and is mainly caused by metabolic disorders and systemic inflammatory responses. Recent studies have indicated that the activation of the mammalian (or mechanistic) target of rapamycin (mTOR) signaling participates in MASH progression by facilitating lipogenesis and regulating the immune microenvironment. Although several molecular medicines have been demonstrated to inhibit the phosphorylation or activation of mTOR, their poor specificity and side effects limit their clinical application in MASH treatment.

View Article and Find Full Text PDF

The complex landscape of immune dysregulation in multisystem inflammatory syndrome in children with COVID-19.

Life Med

August 2024

Institute of Immunology and Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 311100, China.

The immune responses following SARS-CoV-2 infection in children are still under investigation. While coronavirus disease 2019 (COVID-19) is usually mild in the paediatric population, some children develop severe clinical manifestations or multisystem inflammatory syndrome in children (MIS-C) after infection. MIS-C, typically emerging 2-6 weeks after SARS-CoV-2 exposure, is characterized by a hyperinflammatory response affecting multiple organs.

View Article and Find Full Text PDF

Cell surface protein-protein interaction profiling for biological network analysis and novel target discovery.

Life Med

August 2024

Institute of Pediatrics, Children's Hospital of Fudan University, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.

The secretome is composed of cell surface membrane proteins and extracellular secreted proteins that are synthesized via secretory machinery, accounting for approximately one-third of human protein-encoding genes and playing central roles in cellular communication with the external environment. Secretome protein-protein interactions (SPPIs) mediate cell proliferation, apoptosis, and differentiation, as well as stimulus- or cell-specific responses that regulate a diverse range of biological processes. Aberrant SPPIs are associated with diseases including cancer, immune disorders, and illness caused by infectious pathogens.

View Article and Find Full Text PDF

Background: Cholestasis plays a critical role in sepsis-associated liver injury (SALI). Intestine-derived fibroblast growth factor 19 (FGF19) is a key regulator for bile acid homeostasis. However, the roles and underlying mechanisms of FGF19 in SALI are still unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!